$DIXON Dixon Technologies shares surged nearly 6% today to ₹13,161

Dixon Technologies shares surged nearly 6% today to ₹13,161 after brokerage firm Investec raised its target price to ₹16,200, citing strong growth prospects from its entry into speciality EMS and stabilising mobile demand. The stock has gained over 10% in the past five sessions. 📊 Market & Brokerage Updates Current Price (July 6, 2026): ₹13,161 (NSE intraday high) Target Price Raised: Investec revised target to ₹16,200 (≈30% upside). Rating: Maintained Buy recommendation. EPS Estimates: Increased by 6–8% for FY27–FY28. Momentum: Stock has rallied 10% in last 5 sessions, top gainer in Nifty Midcap 100. 🏭 Corporate Developments Speciality EMS Expansion: Dixon entered the speciality electronics manufacturing services (EMS) segment through acquisitions, boosting growth outlook. Mobile Demand: Stabilising as consumers adjust to higher prices; Indian EMS players gaining share from Chinese competitors. Telecom & IT Hardware: Revenue estimates upgraded by Investec. PLI Scheme Impact: EBITDA expected to remain flat in H1 FY27 due to expiry of PLI scheme, but strong recovery anticipated in H2 FY27. 🔑 Growth Drivers Mobile Exports: Expected to rise, supporting earnings upgrades. Vivo JV: Government approval for Dixon’s joint venture with Vivo is in final stages; expected to add 20+ million units annual capacity. Structural Engines: Export momentum, component localisation, IT hardware expansion, and backward integration identified as long‑term growth catalysts. ⚠️ Risks & Watchpoints PLI Scheme Expiry: Short‑term margin pressure in H1 FY27. Component Costs: Rising RAM and laptop component prices may weigh on volumes. Regulatory Approvals: Vivo JV clearance critical for mobile growth trajectory. 📌 Investor Takeaways Dixon is entering a new growth phase with speciality EMS and export expansion. Strong upside potential remains if mobile exports and Vivo JV approval materialize. Near‑term margins may be flat, but H2 FY27 earnings recovery looks promising.